Watch out Ab­b­Vie and J&J, As­traZeneca just took an­oth­er big swing at one of your star can­cer drug fran­chis­es

As­traZeneca re­port­ed Tues­day that its BTK con­tender Calquence (acal­abru­ti­nib) aced a Phase III tri­al as a sec­ond-line ther­a­py for chron­ic lym­pho­cyt­ic leukemia pa­tients, al­low­ing re­searchers …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER